A peer-reviewed five-year indirect comparison associates BRIUMVI with lower modeled disability progression risk than ocrelizumab and ofatumumab. The findings support TG Therapeutics' commercial evidence strategy but cannot establish head-to-head superiority.
The FDA has accepted Roche’s fenebrutinib filing under Priority Review for both relapsing and primary progressive multiple sclerosis, potentially creating a high-efficacy oral alternative across disease forms currently treated very differently.
Teva gains broad rights to PB018 as Polpharma Biologics advances an Ocrevus biosimilar into clinical development for multiple sclerosis.
Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,